Serge Belanger, an analyst from Needham, maintained the Buy rating on Collegium Pharmaceutical. The associated price target remains the same with $46.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Serge Belanger has given his Buy rating due to a combination of factors that highlight the potential of Collegium Pharmaceutical. The company’s upcoming earnings report for the third quarter of 2025 is anticipated to provide insights into its financial and operational performance, particularly regarding the sales trends of its key products like Jornay PM, Xtampza ER, and Belbuca. These updates are crucial as they reflect the company’s ability to maintain and expand its market presence.
Belanger’s confidence in Collegium Pharmaceutical is further bolstered by the company’s valuation, which he believes does not fully capture its growth prospects, profitability, and the enduring value of its assets. Additionally, the company’s successful history of acquiring and integrating new products into its portfolio supports the Buy rating, as it demonstrates a strategic approach to enhancing its product offerings and sustaining long-term growth.
Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of COLL in relation to earlier this year.